CompletedPhase 2NCT00025441
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Principal Investigator
- Heather P. McDowell, MDRoyal Liverpool Children's Hospital, Alder Hey
- Intervention
- dactinomycin(biological)
- Eligibility
- 6-17 years · All sexes
- Timeline
- 1998 – 2010
Study locations (22)
- Centre Leon Berard, Lyon, France
- Our Lady's Hospital for Sick Children, Crumlin, Ireland
- Birmingham Children's Hospital, Birmingham, England, United Kingdom
- Bristol Royal Hospital for Children, Bristol, England, United Kingdom
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
- Saint Bartholomew's Hospital, London, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, London, England, United Kingdom
- Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
- Meyerstein Institute of Oncology at University College of London Hospitals, London, England, United Kingdom
- Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, England, United Kingdom
- Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, England, United Kingdom
- Queen's Medical Centre, Nottingham, England, United Kingdom
- Oxford Radcliffe Hospital, Oxford, England, United Kingdom
- +7 more locations on ClinicalTrials.gov
Collaborators
Children's Cancer and Leukaemia Group · Societe Francaise Oncologie Pediatrique
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00025441 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center